New MRI dye aims to sharpen cancer detection
NCT ID NCT07472491
Summary
This study is testing a new contrast agent called mangaciclanol for MRI scans. It aims to help doctors see and diagnose suspicious areas (lesions) in the brain or body more clearly than with the current standard agent. The trial will enroll 640 adults who are already scheduled for a contrast-enhanced MRI as part of their standard care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KNOWN OR HIGHLY SUSPECTED CENTRAL NERVOUS SYSTEM (CNS) LESION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.